Joined April 2010
- Tweets 4,268
- Following 4,652
- Followers 728
- Likes 10,224
146 Photos and videos
André Jefremow retweeted
Jun 3
I’ve just updated the last 2 years of this IBD trial timeline
I think it may be useful to gain perspective: decades of trial names together reminds us how much the field has evolved and how fast it is still moving
Now including >250 trials🤩
Full quality ibd-eii.com/cheat-sheet/
2
30
100
4,254
André Jefremow retweeted
MUST READ📖
Joint @RomeFoundation & @IOIBD1 RAND/UCLA Recommendations for #Evaluation & #Managmt of #IBD with #IBS-like Symptoms @AGA_Gastro
pubmed.ncbi.nlm.nih.gov/4206…
📝Nomenclature: IBD with IBS-like symptoms
Evaluation🩺 🧫
Therapies
🥗Diet
💊Drugs💉
🧠Brain gut behavioral tx
28
48
4,374
André Jefremow retweeted
5 Oct 2025
One-off application of CAR T-cell therapy leads to long term remission for a range of autoimmune diseases including SLE and more recently, IBD. Is this game changing therapy in the making? #UEGWeek
8
24
107
19,631
André Jefremow retweeted
29 Sep 2025
CAR T-cell therapy was effective for a patient with multi-drug refractory ulcerative colitis.
nejm.org/doi/full/10.1056/NE…
1
7
23
1,593
André Jefremow retweeted
28 Sep 2025
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
2
24
59
4,799
André Jefremow retweeted
28 Sep 2025
The gastroenterology and immunology communities are buzzing after a landmark NEJM publication (Sept 25, 2025) reported the first successful use of autologous CD19 CAR T-cell therapy in ulcerative colitis (UC). The patient, who had exhausted biologics and immunosuppressants, achieved sustained remission with mucosal healing—off all medications—for more than eight months.
So, what exactly is CAR-T, and why is this so exciting for IBD? 👇
9
84
400
34,429
André Jefremow retweeted
25 Sep 2025
Therapeutic B-cell targeting: the next big thing in #IBD treatment for selected pts? @RajaAtreya #MarkusNeurath
🌍✨ #Crohns #Colitis #MedTwitter
@IBD_FloMD @fgomollon @Y_ECCO_IBD @ibddoctor @IBDMD @DignassAxel @RestelliniS
nejm.org/doi/full/10.1056/NE…
15
33
3,382
André Jefremow retweeted
25 Sep 2025
Cellular therapy is making big moves in so many spaces!! 🔥 🎯
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. @NEJM
nejm.org/doi/full/10.1056/NE…
3
9
1,073
André Jefremow retweeted
26 Sep 2025
Exciting times ahead 🥹
26 Sep 2025
WOW @NEJM
CD19 CAR-T led to complete remission (clinical, biochemical, mucosal) in MDR UC
Patient failed on steroids, cyclosporine, 5-ASA, anti-TNF, JAKi, S1Ps, vedo, p19
By day 50 activity index 7↘️0 maintained 14 wks of FU
⬆️7kg
Mild adverse efect resolved spontaneously
link👇
1
8
51
5,139
André Jefremow retweeted
20 Jun 2025
The 3-6-9 rule of normal intestinal diameters 🧠
🔸Small intestine: <3 cm
🔸Large intestine: <6 cm
🔸Caecum: <9 cm
12
373
2,010
138,035
André Jefremow retweeted
17 Sep 2024
1/2
C. DIFFICILE AND LEUKOCYTOSIS
A not uncommon reason for inpatient hematology consultation: a patient (such as case shown in the graphic) with leukemoid reaction (WBC > 10^9/L) who has or turns out to have C. difficile infection (CDI).
3
18
70
6,927
André Jefremow retweeted
25 Jul 2024
Here is my full review of the most impactful papers in IBD so far this year
SEQUENCE study compares Risankizumab (RIS) and Ustekinumab in people with Crohn's Disease who have lost response to an anti-TNT medication (IFX or ADA)
What is the significance of the picture?
4
48
121
29,902
Original Article: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease (SEQUENCE) nej.md/46dtnFY
Editorial: Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation nej.md/4eZJVFc
ALT Diagram of interleukin-23 and interleukin-12 cytokines.
1
60
184
32,920
André Jefremow retweeted
22 Jan 2024
🌟Ever found yourself doubting about IBD new drugs doses? or forgetting Thiopurine metabolism details?
I've been there too
So I thought it could help having "IBD Cheat Sheets" and that is what I did:
ibd-eii.com/ibdcheatsheet
I hope it helps as much as it helps me
1/2
#IBD
34
159
435
94,156
André Jefremow retweeted
29 Jun 2024
Out now 🚨 in @AGA_Gastro is your latest update on selective IL-23p19 inhibition in IBD! Amongst other topics featuring discussion of pathogenesis, PD/PK, efficacy, safety, positioning, and more! Together with @JeanFredericCo1 @MehandruLab & @ryanungaro gastrojournal.org/article/S0…
1
19
53
2,848
André Jefremow retweeted
30 Jun 2024
You've probably heard "don't give lactated ringers because it raises lactate"
This statement is ~98% false, but there's one crucial practice-changing fact that you need to know.
A 🧵 all about lactic acid and lactated ringers!
1/
27
393
1,802
432,112
André Jefremow retweeted
21 Jun 2024
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
@Y_ECCO_IBD @IBD_FloMD @fgomollon
@RPanaccione @DignassAxel
jnj.com/media-center/press-r…
6
25
1,226
André Jefremow retweeted
16 Jun 2024
Congratulations! Fantastic update 🤩
Relevant changes from 2019
✅do not stop biologicals prior surgery (2019 was conditional)
❌no fibrin glue for perianal
✅IFX & ADA for perianal
❓VEDO, UST, RIS, UPA in perianal
And much more relevant data!
Definitely 👍
16 Jun 2024
Hot off the press : the #ECCO 2024 #Guidelines on Therapeutics in #CD: Medical Treatment. Excellently lead by Hannah Gordon and @IBD_MB, in close collaboration with ECCO GuiCom, @efcca and many clinicians globally. @Y_ECCO_IBD
academic.oup.com/ecco-jcc/ad…
6
24
71
9,111
André Jefremow retweeted
16 Jun 2024
Hot off the press : the #ECCO 2024 #Guidelines on Therapeutics in #CD: Medical Treatment. Excellently lead by Hannah Gordon and @IBD_MB, in close collaboration with ECCO GuiCom, @efcca and many clinicians globally. @Y_ECCO_IBD
academic.oup.com/ecco-jcc/ad…
3
93
158
34,720
André Jefremow retweeted
29 May 2024
The small intestinal bacterial overgrowth controversy thickens! 🤺
Article in @NGMJournal challenges:
1️⃣breath testing for #SIBO
2️⃣The #IBS-SIBO connection
Let’s dive in! 🧵
#MedTwitter #GITwitter #microbiome @ANMSociety
onlinelibrary.wiley.com/doi/…
3
33
83
13,216